PDGFRβ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review

Mirela Andrei
Andrei Bandarchuk
Cherif Abdelmalek
Ajay Kundra
Vladimir Gotlieb
Jen Chin Wang

Patient: Male, 37
Final Diagnosis: PDGFRβ-rearranged myeloid neoplasm with eosinophilia
Symptoms: Night sweats • weight loss
Medication: —
Clinical Procedure: —
Specialty: Hematology

Objective: Rare disease

Background: PDGFRβ-positive myeloid neoplasms are rare. Marked leukocytosis (over 100×10⁹/L) with marked eosinophilia (over 10%) has been rarely described in myeloid neoplasms associated with PDGFRβ rearrangement.

Case report: We report a case of 37-year-old man with myeloid neoplasm associated with PDGFRβ rearrangement who presented with marked eosinophilia of 13.3% and leukocytosis with WBC count of 189×10⁹/L. He was found to have PDGFRβ locus rearrangement at 5q32-33 by fluorescent in situ hybridization (FISH). He responded very well to low-dose imatinib therapy. To the best of our knowledge this degree of hypereosinophilia and leukocytosis in a young adult was reported only once previously. Using low dose therapy in treating this condition has rarely been reported and has not been clearly defined. Our case demonstrated that low dose imatinib therapy can be as effective as high dose imatinib therapy in treating PDGFRβ-positive myeloid neoplasms.

Conclusions: The patient presented with very high WBC and eosinophil count rarely reported in a young adult with PDGFRβ-rearranged myeloid neoplasm. The recognition of this rare presentation as a manifestation of PDGFRβ-gene translocation is important, and equally important that low-dose imatinib (100 mg/day) might have the same effect as high dose imatinib (400 mg/day).

MeSH Keywords: Eosinophilia • Myeloid Neoplasm • PDGFRβ Rearrangement

Full-text PDF: http://www.amjcaserep.com/abstract/index/idArt/900623
Background

In 2008, a major revision of the World Health Organization (WHO) included a new molecular classification of myeloid malignancies; a subtype of myeloid neoplasms with eosinophilia (MLN-eo) and abnormalities of PDGFR\(^a\), PDGFR\(^b\) or FGFR1 were described [1]. The more recent 2016 revisions included a new provisional entity – myeloid neoplasm with t(8;9) (p22;q24.1) [2–4]. In particular, as we learned more about the heterogeneous of the clinical presentation of PDGFR\(^b\)-rearranged myeloproliferative neoplasms, genetic and molecular analysis becomes critical for appropriate diagnosis and management of eosinophilic myeloid neoplasms. Myeloid neoplasms and eosinophilia with rearrangement of PDGFR\(^b\) are more common among males, especially males aged 25 to 55 years. Elevated white blood cells (WBCs) with eosinophilia and splenomegaly are frequent features of this disease. A review of the literature found previously reported cases with marked leukocytosis and PDGFR\(^b\)-related eosinophilia were mainly in patients presenting at an older age (more than 50 years old) or very young patients. In this report, we present a case of a 37-year-old man with myeloid neoplasm associated with marked leukocytosis and eosinophilia with PDGFR\(^b\)-locus rearrangement at 5q32-33 and complete hematologic response to low-dose imatinib. Recognizing this rare presentation with marked leukocytosis and eosinophilia secondary to PDGFR\(^b\) rearrangement is important, because effective treatments can be rendered.

Case report

A 37-year-old man was sent from his primary care provider to our emergency department (ED) for further management of abnormal blood work: leukocytosis (WBC 189×10\(^9\)/L, and absolute neutrophil count 149×10\(^9\)/L) with absolute eosinophilia. Complete blood count (CBC) showed red blood cell (RBC) count of 3.44×10\(^12\)/L, hemoglobin of 9.6 g/dL, hematocrit of 30.9%, MCV of 89.9 fl, and platelet count at 112×10\(^9\)/L. The peripheral blood eosinophils were 13.3% with an equivalent absolute eosinophil count (AEC) of 25×10\(^9\)/L, and monocytes were 4.5% with an absolute monocyte count (AMC) of 8.6×10\(^9\)/L. Patient history was significant for weight loss of 20–30 pounds in the previous three months, excessive night sweats, and family history of leukemia (his grandmother). Initial physical examination showed enlarged spleen with 3 cm below left costal margin. There was no lymphadenopathy or hepatomegaly. Further investigations revealed normal serum tryptase, IgE, and troponin. Laboratory results also showed elevated B12, ferritin of 858 ng/mL, LDH 3150, and slightly elevated uric acid and phosphorus. Peripheral blood smear (Figure 1A, 1B) showed marked leukocytosis with all stages of myeloid cells, eosinophilia and mild dysplasia in myeloid cells consistent with the diagnosis of atypical CML. No secondary etiology for eosinophilia was identified. Abdominal computerized tomography (CT) revealed an enlarged spleen with a span of 17.2 cm without any other abnormalities. The bone marrow (Figure 2A, 2B) was hypercellular (>95%) displaying immature and mature eosinophils up to 21% and left shift granulocytosis. Cyto genetic analysis showed normal karyotype 46,XY. There was no evidence of BCR-ABL fusion gene, nor PDGFR\(^a\) or FGFR1 rearrangement by FISH, which were performed by the GenPath lab (NJ). Jak2V617F, MPL 515, CALR, and c-kit D816 V mutational analyses were negative. Negative cyto genetic, FISH, and RT-PCR studies did not support the diagnosis of chronic eosinophilic leukemia (CEL), chronic myeloid leukemia (BCR-ABL+ CML), myeloproliferative neoplasm with PDGFR\(^b\) rearrangement, myeloproliferative neoplasms (non-CML), or myelodysplastic syndrome (MDS). Subsequently, PDGFR\(^b\) FISH testing of bone

Figure 1. Wright’s stain of peripheral blood cells shows increased eosinophil (A) and marked leukocytosis with granulocytes left shift and granulocytic dysplasia (B) (×100 magnification).
marrow cells was done by Vanderbilt University Medical Center using the probe developed by Vysis. It demonstrated abnormal rearrangement of the PDGFR\textsuperscript{b} locus at 5q32-33 in 81% of cells by FISH with no identified partner gene. Applying the current WHO-defined criteria (2015 update and 2016 revision) [3,4], the patient was diagnosed with myeloid neoplasm associated with eosinophilia with PDGFR\textsuperscript{b} abnormality.

While the aforementioned workup for myeloproliferative neoplasm (MPN) was in progress, given the patient’s severe leukocytosis, he was started on hydroxyurea at 1 g/day, along with allopurinol for tumor lysis prevention. Because of persistent elevated WBC, his hydroxyurea was increased to 3 g/day and prednisone at1 mg/kg was added. Hematologic response was obtained two weeks after treatment was initiated: WBC 6.3×10\textsuperscript{9}/L with AEC 1.3×10\textsuperscript{9}/L. At this point, hydroxyurea was discontinued and imatinib 400 mg/day was initiated after PDGFR\textsuperscript{b} rearrangements was detected. Shortly thereafter (10 days), the patient developed leukopenia (WBC 2.5×10\textsuperscript{9}/L) and imatinib was temporary discontinued for approximately 14 days. Prednisone was slowly tapered over a five-week period and imatinib dose was reduced to 100 mg/day. The patient had close follow-up, with blood count monitoring on a weekly basis; medication dose adjustment was made based on blood counts as shown in Figure 3. The patient obtained sustained complete hematologic remission with resolution of leukocytosis and eosinophilia and normalization of spleen size in response to low-dose imatinib therapy for more seven months.

Discussion

PDGFR\textsuperscript{b} positive eosinophilic disorders, as genotypically and phenotypically diverse neoplasms, are extremely rare. The discovery of this PDGFR\textsuperscript{b} rearrangement with molecular abnormality ETV6-PDGFR\textsuperscript{b}, t(5;12) (q33;p13) in 1994, prompted a more comprehensive molecular analysis [5]. Since that time, other translocations have been described and additional genes to

PDGFR\textsuperscript{b} fusion transcript have been identified in the rearrangement of chromosome bands 5q31-q33 [6]. However, molecular identification of PDGFR\textsuperscript{b} fusion genes remains challenging due to the molecular heterogeneity of fusion partners and potential false-negative results by cytogenetic and/or FISH studies. Therefore, a combination of quantitative reverse transcriptase polymerase chain reaction (RT-PCR)-based approaches may be necessary to determine those rare genetic alterations [7–9].

“Myeloid neoplasms harboring PDGFR\textsuperscript{b} fusion” represent a small subset of myeloid neoplasms with eosinophilia that are included in the WHO classification. The revision to the WHO diagnostic criteria in 2008 based on molecular analysis included a different category of myeloid and lymphoid neoplasms with eosinophilia (MLN-eo) and abnormalities of PDGFR\textsuperscript{b}, PDGFR\textsuperscript{b} or FGFR1; there was no major change in the 2016 revision. Phenotypically, the most frequent morphologic presentations of myeloid neoplasms with abnormalities of PDGFR\textsuperscript{b} were: aCML, chronic myelomonocytic leukemia (CML), myelofibrosis, acute leukemia, and chronic eosinophilic leukemia (CEL) [10–12] (Table 1). These spectrums of presentations, even

![Figure 2. Bone marrow aspirate shows hypercellularity with maturing trilineage hematopoiesis (A) (×50 magnification) and prominent eosinophilia (B) (×100 magnification).](image)

![Figure 3. Peripheral blood white blood count (WBC) and absolute eosinophil count (AEC) response to therapy over 10-week duration.](image)
Table 1. Cases of myeloid neoplasm with eosinophilia and PDGFRβ abnormality.

| Diagnosis                        | Age/Sex | WBC (×10^9/L) | Eosinophil (×10^9/L) | % Eosinophil | Reference |
|----------------------------------|---------|---------------|----------------------|--------------|-----------|
| aCML                             | 35 M    | 52,000        | 6,760                | 13           | [36]      |
| aCML                             | 2/F     | 209,000       | 18,810               | 9            | [23]      |
| aCML                             | NA      | NA            | NA                   | NA           | [21]      |
| aCML                             | M       | NA            | NA                   | 27           | [35]      |
| aCML                             | M       | NA            | NA                   | 13           | [35]      |
| aCML                             | 51/M    | NA            | NA                   | 5 to 25%     | [25]      |
| aCML                             | 44/M    | 158,000       | 12,600               | 8            | [19]      |
| aCML                             | 64/M    | 22,400        | 5,600                | 25           | [14]      |
| aCML                             | 65/M    | 37,000        | 0                    | 0            | [14]      |
| aCML                             | M       | NA            | NA                   | Eosinophilia | [35]      |
| aCML                             | 79/M    | 138,000       | 62,100               | 45           | [51]      |
| ALL and MPD                      | 38/M    | NA            | Eosinophilia         | NA           | [46]      |
| AML                              | 36/M    | 3,100         | NA                   | NA           | [42]      |
| AML relapsed-PDGFRβ rearranged   | NA      | NA            | Eosinophilia         | NA           | [31]      |
| AML-M2                           | 5/F     | 1,700         | 0                    | 0            | [14]      |
| AML-M2                           | 74/M    | 1,000         | 20                   | 2            | [14]      |
| CEL                              | 21/M    | 21,600        | 8,000                | 37           | [39]      |
| CEL                              | 43/M    | NA            | NA                   | NA           | [28]      |
| CEL                              | 70/M    | 55,900        | 17,900               | 32           | [29]      |
| CMML                             | 29/M    | 173,000       | NA                   | NA           | [33]      |
| CMML                             | 35/F    | 386,000       | 15,400               | 4            | [40]      |
| CMML                             | 54/M    | NA            | Eosinophilia         | NA           | [32]      |
| CMML                             | NA      | NA            | NA                   | NA           | [49]      |
| CMML                             | 17/M    | NA            | NA                   | NA           | [30]      |
| CMML                             | 57/M    | 181,000       | 7,240                | 4            | [14]      |
| CMML                             | NA      | NA            | NA                   | NA           | [5]       |
| CMML                             | 29/M    | 59,200        | NA                   | NA           | [52]      |
| CMML                             | 77/M    | 12,000        | 120                  | 1            | [53]      |
| JMML                             | 18 months/M | 25,400 | 2,790 | 11 | [37] |
| JMML                             | 18 months/M | NA | NA | NA | [47] |
| Leukocytosis                      | 40/M    | 18,000        | 1,100                | 6.1          | [28]      |
| Leukocytosis                      | 35/M    | 60,000        | NA                   | NA           | [28]      |
| MDS                              | M       | NA            | NA                   | No Eosinophilia | [35]      |
| MDS                              | 63/F    | 1,000         | 20                   | NA           | [14]      |
Table 1 continued. Cases of myeloid neoplasm with eosinophilia and PDGFRα abnormality.

| Diagnosis   | Age/Sex       | WBC (×10^3/L) | Eosinophil (×10^3/L) | % Eosinophil | Reference |
|------------|---------------|---------------|----------------------|--------------|-----------|
| MDS        | 67/M          | 2,200         | 0                    | 0            | [14]      |
| MDS/AML    | M             | NA            | NA                   | 8            | [35]      |
| MDS/AML    | M             | NA            | NA                   | No eosinophilia | [35]      |
| MDS/MPD    | 11 months/F   | 43.9          | Marked eosinophilia  | NA           | [34]      |
| MMM        | 67/M          | 1,700         | 1700                 | 1            | [14]      |
| MMM        | 67/M          | 5,700         | 57                   | 1            | [14]      |
| MPN        | 32/M          | 80,000        | 7,820                | 10           | [22]      |
| MPN        | 50/M          | 52,000        | 4,800                | 9.2          | [22]      |
| MPN        | 68/M          | 41,000        | 1,640                | 4            | [22]      |
| MPN        | 4/M           | 9,000         | 4,100                | 44           | [22]      |
| MPN        | M             | NA            | NA                   | NA           | [35]      |
| MPN        | F             | NA            | NA                   | 6            | [35]      |
| MPN        | 65/F          | 62,000        | 3,500                | 0.5          | [43]      |
| MPN        | 67/M          | 46,500        | 12,600               | 27           | [43]      |
| MPN        | 13 months/M   | 44,000        | 12,000               | 27           | [43]      |
| MPN        | 6/M           | 9300          | 4100                 | 44           | [43]      |
| MPN        | 82/F          | NA            | NA                   | NA           | [26]      |
| MPN        | 8 patients – Median age 55 (21–78) | NA | NA | NA | [44] |
| MPN        | 34 weeks/M    | 37,600        | 5,600                | 14.8         | [27]      |
| MPN        | 4/M           | 15,600        | 3,900                | 25           | [27]      |
| MPN        | 26 patients with median age 50 (0.9–78) | Median 51,000 (4,000–138,000) | Median 3,500 (700–12,000) | NA | [15] |
| MPN        | 50/M          | 52,000        | 4,800                | 9.2          | [24]      |
| MPN        | 69/M          | 41,000        | 1,600                | 3.9          | [24]      |
| MPN        | 32/M          | 80,000        | 7,800                | 9.7          | [24]      |
| MPN        | 51/M          | 20,600        | 1,800                | 8.7          | [24]      |
| MPN        | 56/M          | 80,000        | 3,200                | 4            | [24]      |
| MPN        | 36/M          | 56,900        | 5,000                | 8.7          | [24]      |
| MPN        | 57/M          | 66,000        | 5,000                | 7.5          | [24]      |
| MPN        | 48/M          | 10,800        | 8,400                | 77           | [24]      |
| MPN        | 6/M           | 9,200         | 4,100                | 44           | [24]      |
| MPN        | 68/M          | 46,500        | 12,600               | 27           | [24]      |
Table 1 continued. Cases of myeloid neoplasm with eosinophilia and PDGFR\textsuperscript{b} abnormality.

| Diagnosis           | Age/Sex | WBC (×10\textsuperscript{9}/L) | Eosinophil (×10\textsuperscript{9}/L) | % Eosinophil | Reference |
|---------------------|---------|---------------------------------|--------------------------------------|--------------|-----------|
| MPN                 | 78/M    | 138,000                         | 5,400                                | 3.9          | [24]      |
| MPN                 | 65/M    | 62,000                           | 3,500                                | 5.6          | [24]      |
| MPN                 | 45/M    | NA                              | 1,100                                | NA           | [41]      |
| MPN                 | 73/M    | 70,500                           | 2,800                                | 1.9          | [41]      |
| MPN                 | 48/M    | 94,000                           | 6,580                                | 7            | [20]      |
| MPN                 | 80/M    | 13,000                           | 3,700                                | 29           | [48]      |
| MPN                 | 53/M    | 56,000                           | 5,600                                | 10           | [48]      |
| MPN                 | 75/M    | 60,000                           | 27,600                               | 46           | [48]      |
| MPN                 | 67/M    | 21,000                           | 9,240                                | 44           | [8]       |
| MPN                 | 59/M    | 10,000                           | 4,700                                | 47           | [8]       |
| MPN                 | 45/F    | 34,000                           | >6,800                               | 20-40        | [8]       |
| Eos-MPN             | 40/M    | 19,000                           | 1,800                                | 9.4          | [16]      |
| MPN                 | 45/M    | 15,100                           | 4,700                                | 31.1         | [50]      |
| MPN with thrombocytopenia | 67/M | No leukocytosis                   | No                                   | NA           | [45]      |
| MPN                 | F       | NA                              | NA                                   | 2 to 16      | [35]      |
| MPN/CMMoL           | 42/M    | 64,900                           | 3,245                                | 5            | [38]      |
| Myeloma/MDS         | 74/M    | 1,100                            | 22                                   | 2            | [14]      |
| MPN,34 cases (CMMoL, CEL, aCML) | Age 8–80 years | 10.7–97,000                      | NA                                   | 9 to 42      | [16]      |
| RA                  | 82/M    | 4,500                            | 50                                   | 1.1          | [14]      |

MPN – BCR-ABL negative myeloproliferative disorders; CMMoL – chronic myelogenous leukemia; CEL – chronic neutrophilic leukemia; MDS – myelodysplastic disease; AML – acute myelogenous leukemia; MMM – myelofibrosis, myeloid metaplasia; RA – refractory anemia.

though heterogeneous, have remarkable associations, particularly peripheral blood and bone marrow hypereosinophilia. The rarity of the condition requires us to know exactly how to diagnose this disease. After the secondary causes are excluded, the next step is to screen peripheral blood for the distinct driving molecular alterations of clonal eosinophilia. The most frequent recurrent aberration is the FIP1L1-PDGFR\textsuperscript{a} fusion gene, detectable in 5–15% of all cases [13]. Molecular absence of FIP1L1-PDGFR\textsuperscript{a} fusion gene indicates the need to evaluate for other rare abnormalities of PDGFR\textsuperscript{b} given the critical therapeutic implications.

A comprehensive retrospective analysis of all cytogenetic studies performed at the Mayo Clinic over a 15-year period identified 25 cases of t(5;12) among 56,709 cytogenetic studies. The clinical and laboratory features were available for only 11 patients. Associated peripheral eosinophilia was found in three out of 11 patients, who were diagnosed as atypical chronic myelocytic disorder (aCMD), chronic myelomonocytic leukemia (CMMoL), and myelofibrosis with myelocytic metaplasia (MMM). Of note, all three patients were elderly (67, 64, and 57 years old). Two out of three patients presented with WBC >150×10\textsuperscript{9}/L; one out of three patients had 25% eosinophil count (diagnosed as aCMD); and all three patients displayed monocytosis (diagnosed as MMM, CMMoL) [14]. An updated and expanded analysis of a cohort of 26 patients treated with imatinib was presented by Cheah et al. [15]. Most patients were males with median eosinophil count at diagnosis of 3,500×10\textsuperscript{9}/L that ranged from 0.7–12×10\textsuperscript{9}/L and PDGFR\textsuperscript{b} fusion genes associated with translocations involving chromosome 5 confirmed on metaphase cytogenetic. Of note, all PDGFR\textsuperscript{b} patients had 5q31-33 abnormalities and 78% had a t(5;12) translocation, emphasizing the need of cytogenetic analysis when clonal hypereosinophilia is suspected. Successful use of imatinib was demonstrated, with the most common starting dose of 400 mg. A 10-year overall survival rate of 90% was reported.
and durable long-term remissions after a median follow-up of 10.2 years. As stated recently by Macaferri et al. [16], the optimal dose of imatinib in Eo-MPN with PDGFRB rearrangement has not yet been clearly defined.

By reviewing the literature of case reports and case series, we observed that 400 mg/day imatinib was usually given and elicited durable hematologic and molecular remission. Although lower doses (100–300 mg/day) might be sufficient to achieve a molecular remission in some patients. However, this observation was based on a very small number of cases. More than 30 variants of PDGFRB fusion partners were identified and all appeared responsive to imatinib. The underdetectable or undetectable fusion gene, patient's clinical features, prior therapy, and timing to start the therapy since diagnosis, all might influence the dose of imatinib. Thus, the optimal dose of imatinib that sustains a hematologic and molecular remission was not defined. Our case demonstrated a good hematologic response to low dose imatinib, suggesting that low dose can be equally as effective as high dose. The durability of response to imatinib obviates the need for allogeneic stem cell transplantation.

In addition to the (5;12) translocation, several other cases with 5q31-5q33 translocations have been reported, with or without PDGFRB involvement [17]. In one study, of the 34 patients with t(5;12) and PDGFRB rearrangement, only five patients had eosinophils >20% and were diagnosed as CML or CMML (one case with AML). All patients had a WBC <100×10^9/L and most of them were elderly. A remarkable feature of variant translocations involving 5q31-5q33, was a greater diversity of phenotype. The frequency of chromosomal changes in aCML was more variable, ranging from 20–88% [18]. To the best of our knowledge, as shown in Table 1, only one similar case of PDGFRB-positive myeloid neoplasm with marked leukocytosis and eosinophilia in a young adult has been reported. The patient, a 44-year-old man had a significantly elevated WBC of 158×10^9/L with 8% eosinophil count [19]. Importantly, upon literature review, it was noticed that as opposed to young adults, pediatric and some elderly patients with PDGFRB associated MPN are more likely to present with marked leukocytosis and eosinophilia (Table 1) [14,15,19–53]. However, our observation is still open to discussion given the rarity of these cases.

Conclusions

Our case report is relevant because of the rarity of marked leukocytosis and eosinophilia secondary to PDGFRB rearrangement in young adults, with normal conventional cytogenetic analysis. To the best of our knowledge, this is the second case of PDGFRB-positive myeloid neoplasm with marked eosinophilia in a young adult. Despite the rare frequency (<1%) of PDGFRB rearrangements, the rapid and durable response to imatinib highlights the importance of an accurate molecular workup in this entity. Importantly, the molecular pathophysiology and advances in standard therapy have changed the view of transplantation for this disease. Hence, we report the hematologic and molecular characteristics of a patient with PDGFRB-associated marked eosinophilia. The challenge is to make an early diagnosis given the therapeutic implications of long-term observation of imatinib efficacy. One key unanswered question is the correlation of age and marked leukocytosis/eosinophilia; this is an area which deserves further investigation.

References:

1. Brain BI, Gilliland DG, Horny H-P, Vardiman JW. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRα, PDGFRβ, or FGFR1. In: Swerdlow S, Harris NL, Stein H et al. (eds.), World Health Organization classification of tumors of hematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2008; 68–73
2. Patterer V, Schnittert S, Kern W et al: Hematologic malignancies with PCMI-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRβ, PDGFRB and FGFR1. Ann Hematol, 2013; 92(6): 759–69
3. Bain BI, Ahmad S: Should myeloid and lymphoid neoplasms with PCMI-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol, 2014; 166(6): 809–17
4. Arber DA, Orazi A, Hasserjian R et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood, 2017(20): 2391–405
5. Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGFR receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell, 1994; 77: 307–16
6. Arefi M, Garcia JL, Penarrubia NJ et al: Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement. Eur J Haematol, 2012; 89(1): 37–41
7. Erben P, Gosenca D, Muller MC et al: Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica, 2010; 95: 738–44
8. Walz C, Metzgeroth G, Haferlach C et al: Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor B gene. Haematologica, 2007; 92: 163–69
9. Willis TG, Jadayel DM, Coignet LJA et al: Rapid molecular cloning of rearrangements of the IGHJ locus using long-distance inverse polymerase chain reaction. Blood, 1997; 90: 2456–64
10. Tokita K, Maki K, Tadokoro J et al: Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinibmesylate therapy. Leukemia, 2007; 21(1): 190–92
11. Lengline E, Beldjord K, Dombret H et al: Successful tyrosine kinase therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica, 2013; 98(11): e146–48
12. Tefferi A, Triche J, Orazi A et al: Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood, 2007; 110: 1092–97
13. Gotlib J, Cools J: Five years since the discovery of FIP1L1-PDGFA: What we have learned about the fusion and other molecularly defined eosinophilias. Leukemia, 2008; 22(11): 1999–2010
31. Abe A, Emi N, Tanimoto M et al: Fusion of the platelet-derived growth factor 1 to platelet-derived growth factor receptor beta. Acta Haematologica, 2002; 107: 113–22
32. Gotlib J, Maxson JE, George TJ, Tynier JW: The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood, 2013; 122(10): 1707–11
33. Garcia JS, Font de Mora J, Hernandez JM et al: Imatinib mesylate elicits positive clinical response in atypical myeloid leukemia involving the platelet-derived growth factor receptor beta. Blood, 2003; 102: 2699–700
34. Kulkarni S, Heath C, Parker S et al: Fusion of HD/DS15170 to the platelet-derived growth factor receptor beta in CBR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;p21). Cancer Research, 2000; 60: 3592–98
35. Chmielecki J, Peifer M, Viale A et al: Systematic screen for tyrosine kinase fusion oncogenes. Leukemia, 2016; 30(4): 738–44
36. Vizmanos L, Novo FJ, Roma P et al: NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(1; 5)(q23;q34) and an imatinib-responsive myeloproliferative disorder. Cancer Gene Therapy, 2003; 120(2): 251–56
37. Morerio C, Acquila M, Rosanda C et al: HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonoerythroid leukemia with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes Chromosomes Cancer, 2012; 51(1): 54–65
38. Erben P, Gosenca D, Müller MC et al: Screening for diverse PDGFRα or PDGFRβ fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica, 2010; 95(5): 738–44
39. Medves S, Dufohux FP, Ferrant A et al: KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloproliferative disease associated with severe thrombocytopenia. Leukemia, 2010; 24(5): 1052–55
40. Trisolini SM, Istituto IEO: A PDGFRB-positive acute myeloid malignancy. Leukemia, 2008; 22: 216–18
41. Hidalgo-Curtis C, Apperley JF, Stark A et al: Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib – responsive myeloproliferative neoplasms. Br J Haematol, 2010; 148: 268–73
42. Greipp PT, Dewald GW, Teffteri A: Prevalence, breakpoint distribution, and clinical correlates of t(5;12). Cancer Genetics and Cytogenetics, 2004; 153: 170–72
43. Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGFRα receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell, 1994; 77: 307–16
44. Abe A, Emi N, Tanimoto M et al: Fusion of the platelet-derived growth factor receptor β to a novel gene CEV14 in chronic myelogenous leukemia after clonal evolution. Blood, 1997; 90: 4271–77
45. Ross DM, Altamura HK, Hahn CN et al: Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNP1-PDGFRB fusion gene. Leukemia, 2015; 30: 1402–5
46. Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGFRα receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12). Cancer Genetics and Cytogenetics, 1994; 77: 307–16
47. Ross BTS, Bernard OA, Berger R, Gilliland DG: Fusion of huntingtin interacting protein 1 to platelet-derived growth factor receptor β (PDGF βR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood, 1998; 91: 4419–26
48. Steer EJ, Cross NCP: Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor beta. Acta Haematologica, 2002; 107: 113–22
49. Wittman B, Horan J, Baxter J et al: A 2-year-old with atypical CML with a t(5;17)(q33-34;q11.2). Genes Chromosomes Cancer, 2009; 48: 179–83
50. Group GV, Division CS, Cancer A: A new NDE1/PDGFRB fusion transcript under chronic eosinophilic leukemia. Leukemia, 2006; 20: 1623–24
51. Hidalgo-Curtis C, Apperley JF, Stark A et al: Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib – responsive myeloproliferative neoplasms. Br J Haematol, 2010; 148: 268–73
52. Wilkinson K, Velloso ER, Lopes LF et al: Cloning of the t(1; 5) (q23; q33) in a myeloproliferative disorder associated with eosinophilia. Involvement of PDGFRB and response to imatinib. Blood, 2003; 102: 4187–90
53. Bella GC, Padron E: Detection of a PDGFRB fusion in refractory CMML with marked eosinophilia: A case for broad spectrum tumor profiling. Leuk Res Rep, 2015; 4(2): 70–71
54.GroupName M, et al.: PDGFRα-rearranged myeloid neoplasm with marked eosinophilia... © Am J Case Rep, 2017; 18: 173-180